Literature DB >> 11854908

SF/HGF-c-Met autocrine and paracrine promote metastasis of hepatocellular carcinoma.

Q Xie1, K D Liu, M Y Hu, K Zhou.   

Abstract

AIM: To explore the role of SF/HGF-Met autocrine and paracrine in metastasis of hepatocellular carcinoma (HCC).
METHODS: SF/HGF and c-met transcription and protein expression in HCC were examined by RT-PCR and Western Blot in 4 HCC cell lines, including HepG2, Hep3B, SMMC7721 and MHCC-1, the last cell line had a higher potential of metastasis. sf/hgf cDNA was transfected by the method of Lipofectin into SMMC7721. SF/HGF and c-met antibody were used to stimulate and block SF/HGF-c-met signal transduction. Cell morphology, mobility, and proliferation were respectively compared by microscopic observation, wound healing assay and cell growth curve.
RESULTS: HCC malignancy appeared to be relative to its met-SF/HGF expression. In MHCC-1, c-met expression was much stronger than that in other cell lines with lower potential of metastasis and only SF/HGF autocrine existed in MHCC-1. After sf/hgf cDNA transfection or conditioned medium of MHCC-1 stimulation, SMMC7721 changed into elongated morphology, and the abilities of proliferation (P < 0.05) and mobility increased. Such bio-activity could be blocked by c-met antibody (P < 0.05).
CONCLUSION: The system of SF/HGF-c-met autocrine and paracrine played an important role in development and metastasis potential of HCC. Inhibition of SF/HGF-c-met signal transduction system may reduce the growth and metastasis of HCC.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11854908      PMCID: PMC4695601          DOI: 10.3748/wjg.v7.i6.816

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  51 in total

1.  The multisubstrate docking site of the MET receptor is dispensable for MET-mediated RAS signaling and cell scattering.

Authors:  D Tulasne; R Paumelle; K M Weidner; B Vandenbunder; V Fafeur
Journal:  Mol Biol Cell       Date:  1999-03       Impact factor: 4.138

2.  Hepatocyte growth factor gene therapy of liver cirrhosis in rats.

Authors:  T Ueki; Y Kaneda; H Tsutsui; K Nakanishi; Y Sawa; R Morishita; K Matsumoto; T Nakamura; H Takahashi; E Okamoto; J Fujimoto
Journal:  Nat Med       Date:  1999-02       Impact factor: 53.440

3.  Expression of the c-met proto-oncogene and its ligand, hepatocyte growth factor, in Hodgkin disease.

Authors:  L Teofili; A L Di Febo; F Pierconti; N Maggiano; M Bendandi; S Rutella; A Cingolani; N Di Renzo; P Musto; S Pileri; G Leone; L M Larocca
Journal:  Blood       Date:  2001-02-15       Impact factor: 22.113

4.  Mechanism of retarded liver regeneration in plasminogen activator-deficient mice: impaired activation of hepatocyte growth factor after Fas-mediated massive hepatic apoptosis.

Authors:  M Shimizu; A Hara; M Okuno; H Matsuno; K Okada; S Ueshima; O Matsuo; M Niwa; K Akita; Y Yamada; N Yoshimi; T Uematsu; S Kojima; S L Friedman; H Moriwaki; H Mori
Journal:  Hepatology       Date:  2001-03       Impact factor: 17.425

5.  Hepatocyte growth factor and vitamin D cooperatively inhibit androgen-unresponsive prostate cancer cell lines.

Authors:  L R Qadan; C M Perez-Stable; R H Schwall; K L Burnstein; R C Ostenson; G A Howard; B A Roos
Journal:  Endocrinology       Date:  2000-07       Impact factor: 4.736

6.  In vivo molecular imaging of met tyrosine kinase growth factor receptor activity in normal organs and breast tumors.

Authors:  M Shaharabany; R Abramovitch; T Kushnir; G Tsarfaty; M Ravid-Megido; J Horev; R Ron; Y Itzchak; I Tsarfaty
Journal:  Cancer Res       Date:  2001-06-15       Impact factor: 12.701

7.  c-MET expression in myofibroblasts: role in autocrine activation and prognostic significance in lung adenocarcinoma.

Authors:  M Tokunou; T Niki; K Eguchi; S Iba; H Tsuda; T Yamada; Y Matsuno; H Kondo; Y Saitoh; H Imamura; S Hirohashi
Journal:  Am J Pathol       Date:  2001-04       Impact factor: 4.307

8.  The geldanamycins are potent inhibitors of the hepatocyte growth factor/scatter factor-met-urokinase plasminogen activator-plasmin proteolytic network.

Authors:  C P Webb; C D Hose; S Koochekpour; M Jeffers; M Oskarsson; E Sausville; A Monks; G F Vande Woude
Journal:  Cancer Res       Date:  2000-01-15       Impact factor: 12.701

9.  Hepatocyte growth factor secreted by prostate-derived stromal cells stimulates growth of androgen-independent human prostatic carcinoma cells.

Authors:  K Nakashiro; M Okamoto; Y Hayashi; R Oyasu
Journal:  Am J Pathol       Date:  2000-09       Impact factor: 4.307

10.  Met-HGF/SF mediates growth arrest and differentiation in T47D breast cancer cells.

Authors:  D Ronen; R T Altstock; M Firon; L Mittelman; T Sobe; J H Resau; G F Vande Woude; I Tsarfaty
Journal:  Cell Growth Differ       Date:  1999-02
View more
  13 in total

1.  Hepatocyte growth factor upregulation promotes carcinogenesis and epithelial-mesenchymal transition in hepatocellular carcinoma via Akt and COX-2 pathways.

Authors:  Olorunseun O Ogunwobi; Chen Liu
Journal:  Clin Exp Metastasis       Date:  2011-07-10       Impact factor: 5.150

2.  The membrane-cytoskeleton organizer ezrin is necessary for hepatocellular carcinoma cell growth and invasiveness.

Authors:  Yan Zhang; Mei-Yu Hu; Wei-Zhong Wu; Zhi-Jun Wang; Kang Zhou; Xi-Liang Zha; Kang-Da Liu
Journal:  J Cancer Res Clin Oncol       Date:  2006-06-20       Impact factor: 4.553

3.  Epithelial-to-mesenchymal transition of murine liver tumor cells promotes invasion.

Authors:  Wei Ding; Hanning You; Hien Dang; Francis LeBlanc; Vivian Galicia; Shelly C Lu; Bangyan Stiles; C Bart Rountree
Journal:  Hepatology       Date:  2010-09       Impact factor: 17.425

4.  Expression of IGF-II in early experimental hepatocellular carcinomas and its significance in early diagnosis.

Authors:  Zheng Wang; You-Bing Ruan; Yang Guan; Sheng-Hong Liu
Journal:  World J Gastroenterol       Date:  2003-02       Impact factor: 5.742

Review 5.  Genetically modified animal models recapitulating molecular events altered in human hepatocarcinogenesis.

Authors:  Aránzazu Sánchez; Isabel Fabregat
Journal:  Clin Transl Oncol       Date:  2009-04       Impact factor: 3.405

6.  The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma.

Authors:  Tanguy Y Seiwert; Ramasamy Jagadeeswaran; Leonardo Faoro; Varalakshmi Janamanchi; Vidya Nallasura; Mohamed El Dinali; Soheil Yala; Rajani Kanteti; Ezra E W Cohen; Mark W Lingen; Leslie Martin; Soundararajan Krishnaswamy; Andres Klein-Szanto; James G Christensen; Everett E Vokes; Ravi Salgia
Journal:  Cancer Res       Date:  2009-03-24       Impact factor: 12.701

Review 7.  Input of microenvironmental regulation on colorectal cancer: role of the CCN family.

Authors:  Cheng-Chi Chang; Been-Ren Lin; Tai-Sheng Wu; Yung-Ming Jeng; Min-Liang Kuo
Journal:  World J Gastroenterol       Date:  2014-06-14       Impact factor: 5.742

Review 8.  The role of hepatocyte growth factor in corneal wound healing.

Authors:  Hidetaka Miyagi; Sara M Thomasy; Paul Russell; Christopher J Murphy
Journal:  Exp Eye Res       Date:  2017-10-10       Impact factor: 3.467

Review 9.  Oncological benefits of portal vein embolization for patients with hepatocellular carcinoma.

Authors:  Toru Beppu; Kensuke Yamamura; Hirohisa Okabe; Katsunori Imai; Hiromitsu Hayashi
Journal:  Ann Gastroenterol Surg       Date:  2020-12-13

Review 10.  Gangliosides as Signaling Regulators in Cancer.

Authors:  Norihiko Sasaki; Masashi Toyoda; Toshiyuki Ishiwata
Journal:  Int J Mol Sci       Date:  2021-05-11       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.